Innovus Pharma (INNV): Targeting $3+ Billion Markets with 13 Commercial Products
Most micro- and small-cap biotechnology firms are development-stage opportunities with a lengthy commercialization timeline. For investors, these companies have relatively high risks due to the high costs and uncertainty of regulatory approval.
View full press release